🇺🇸 FDA
Patent

US 11518818

Therapeutic anti-IgE antibodies and methods and compositions thereof

granted A61KA61K2039/505A61P

Quick answer

US patent 11518818 (Therapeutic anti-IgE antibodies and methods and compositions thereof) held by The Regents of the University of California expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/505, A61P, A61P37/06, A61P37/08